Complain about a product or service

Compound Can Identify Prostate Cancer

Finding could make diagnosis more precise

February 13, 2009

• Study Links Prostate Cancer to Single Rogue Cell • PSA Testing May Be Unnecessary for Some Older Men • Compound Can Identify Prostate Cancer • Improved PSA Tests May Better Determine Prostate Cancer Risk • Vitamins Don't Cut Prostate Cancer Risk • Aspirin May Lower PSA Levels in Men • FDA Approves New Overactive Bladder Drug • New Prostate Surgical Techniques Often "Over-Promoted" • Feds Approve Drug for Enlarged Prostate • New Prostate Cancer Treatment Shows Promise • Broccoli Reduces Prostate Cancer Risk, Study Finds • Celebrex-Lipitor Combo May Halt Prostate Cancer • Exercise May Speed Prostate Tumor Growth • Soy Compound May Halt Spread of Prostate Cancer • Obesity Linked to Higher Prostate Cancer Mortality • Red Wine May Fight Prostate Cancer • Enlarged Prostate Doesn't Mean Cancer • Hopkins Researchers Claim Better Blood Test for Prostate Cancer • Severe Form of Enlarged Prostate Disease Discovered • Tomato-Broccoli Combo Can Help Shrink Prostate Cancers • Weight Gain Increases Risk of Dying from Prostate Cancer • Smoking Linked to Complications in Prostate Cancer Treatment • Newer Approach Urged in Screening for Aggressive Prostate Cancer • Aspirin May Prevent or Delay Enlarged Prostate • Hopkins Researchers Find Better Blood Test for Prostate Cancer • Prostate Radiation May Cause Problems Later • New Test Detects Prostate Cancer Spread Earlier • Castration May Be Advised in Advanced Prostate Cancer • Radiation Therapy May Be Best for Younger Prostate Cancer Patients • Study Recommends More Prostate Biopsies • Delayed Surgery May Be OK for Some Prostate Cancer Patients • Study: PSA Test Doesn't Improve Prostate Cancer Survival Rate • Prostate Cancer Genes Identified • Annual Prostate Cancer Screening Test Appears to Save Lives • FDA Panel Rejects Prostate Cancer Pill • PSA Test Still Useful, Hopkins Study Finds • No "Normal" PSA Level: Study • New Prostate Cancer Test Shows Promise • Lifestyle and Diet May Stop or Reverse Prostate Cancer Progression

Researchers have determined that a molecule produced by the body's metabolism could be used to differentiate between benign prostate tissue vs. localized and metastatic prostate cancer.

They also found that this molecule, known as sarcosine, may be associated with prostate cancer invasiveness and aggressiveness. The findings, reported by researchers at the Michigan Center for Translational Pathology, appear in the current issue of Nature.

"Current biomarkers for detection or progression of prostate cancer are not as precise as we would like. Therefore, a more accurate indicator of cancer is of great interest," said Sudhir Srivastava, Ph.D., chief of the National Cancer Institute’s Cancer Biomarkers Research Group. "Sarcosine and some other select metabolites may be excellent indicators of cancer progression."

Multiple complex molecular events characterize cancer development and progression. Determining which molecular networks dictate whether cancer will be confined to the prostate or spread to other parts of the body could lead to the identification of critical biomarkers associated with prostate cancer invasion and aggressiveness.

Although many genes and proteins related to cancer have been extensively characterized by genomic and proteomic studies, little is known about metabolomic changes that mark a tumor's progression.

Metabolomics, upon which this current finding is based, is the study of the unique chemical fingerprints that cellular processes leave behind, which can help scientists understand the makeup of a cell.

One of the challenges scientists currently face is integrating genomic, proteomic, and metabolomic information to give a more complete picture of living organisms and the diseases that afflict them.

The researchers profiled more than 1126 metabolites from 262 clinical samples related to prostate cancer. These profiles enabled researchers to distinguish between benign prostate tissue, clinically localized prostate cancer, and metastatic disease. Sixty metabolites were identified in localized and/or metastatic prostate tumors that were not present in benign prostate tissue.

Ultimately, six metabolites, including sarcosine, were found to be significantly elevated during progression from benign tissue to localized cancer to metastatic disease. Sarcosine was also detected in the urine of men with prostate cancer. Because this metabolite showed progressive elevation from benign tissue to localized prostate cancer to metastatic disease, it was selected for further study.

In their analysis, the researchers found that sarcosine levels were higher in invasive prostate cancer cells than in benign prostate cells. Moreover, the addition of sarcosine to benign prostate cells caused them to become invasive.

By manipulating levels of the enzymes that regulate sarcosine metabolism, the researchers found they were able to control the invasiveness of benign and malignant prostate cells.

"Components of the sarcosine pathway could serve as novel avenues for therapeutic intervention," said Arul M. Chinnaiyan, M.D., Ph.D., Michigan Center for Translational Pathology at the University of Michigan, Ann Arbor. "Our next step will be to confirm these findings in a greater number of specimens and to have our results validated by other laboratories."

Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.

Share		Follow us on Twitter.